non-Sq Pembro+PEMˆΫŽ—Γ–@
€–Ϊ–Ό Šξ€—Κ ’PˆΚ }ަ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 @ @ @ @ @ @ @
‘S‘ΜƒXƒPƒWƒ…[ƒ‹ œ ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x ‹x @ @ @ @ @ @ @
ƒLƒCƒgƒ‹[ƒ_ 200 mg/‡u š @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
ƒyƒƒgƒŒƒLƒZƒh 500 mg/‡u š @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
@ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
@ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
@ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
y’ˆΣƒ`ƒ…ƒEƒCŽ–€ƒWƒRƒEz
non-Sq@Pembro+CBDCA+PEMŒγƒS‚ΜˆΫŽŽ‘—ΓƒCƒWƒ`ƒŠƒ‡ƒE@
•a¨isƒrƒ‡ƒEƒZƒCƒVƒ“ƒRƒE‚ά‚ΕŒp‘±ƒPƒCƒ]ƒN